A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of BB3 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Terevalefim (Primary)
Indications Acute kidney injury
Focus Proof of concept; Therapeutic Use
Acronyms GUARD
Sponsors Angion Biomedica; Elicio Therapeutics

Most Recent Events

01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
10 Dec 2021 Results presented in an Angion Biomedica and Vifor Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight